Source comparison
BPC-157 for Elbow Tendinitis Research: Mechanism Comparison
BPC-157 (preclinical) VEGF/bFGF upregulation, FAK-paxillin pathway activation Increased type I collagen deposition, organized fiber alignment Modulates NO pathways. Reduces inflammatory NO, maintains angiogenic NO 14–21 days to 80%+ baseline strength in animal
This comparison does not assign a generated winner or score.
- BPC-157 (preclinical)
- VEGF/bFGF upregulation, FAK-paxillin pathway activation
- Increased type I collagen deposition, organized fiber alignment
- Modulates NO pathways. Reduces inflammatory NO, maintains angiogenic NO
- 14–21 days to 80%+ baseline strength in animal models
- Strongest mechanistic evidence for tissue repair; zero human RCT data limits clinical translation
- Corticosteroid injection
- COX enzyme inhibition, suppression of inflammatory cytokines
- Inhibits fibroblast activity, reduces collagen synthesis
- Potent short-term anti-inflammatory effect
- Pain relief in 48–72 hours; no improvement in structural healing
- Effective symptom management; documented risk of tendon weakening and rupture with repeated use
- Platelet-Rich Plasma (PRP)
- Delivery of autologous growth factors (PDGF, TGF-β, VEGF)
- Stimulates type I collagen production
- Mild to moderate anti-inflammatory via growth factor signaling
- 6–12 weeks for symptom improvement; variable structural changes
- Human RCT evidence exists but inconsistent results; preparation protocols vary widely affecting efficacy
- Physical therapy (eccentric loading)
- Mechanical stimulus triggers collagen remodeling, increased tenocyte mechanotransduction
- Gradual increase in organized collagen deposition
- Minimal direct anti-inflammatory effect
- 12–16 weeks for symptom resolution; progressive strength gains
- Gold standard conservative treatment with strongest human evidence; requires patient compliance and time